Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market, Size, Share, Epidemiology, Forecast till 2030

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market, Size, Share, Epidemiology, Forecast till 2030

“DelveInsight”
DelveInsight’s ‘Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the EGFR NSCLC, historical and forecasted epidemiology as well as the EGFR NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC.   

Epidemiology Insights included in the report 

  • Total incident population of NSCLC in 7MM was 484,726 in 2017
  • The incident cases of EGFR mutation in the United States in 2017 was 37,370
  • The incident population of EGFR-NSCLC in the United States contributed around 34% of the total population of EGFR mutated NSCLC in the 7MM in 2017
  • Among the EU5 countries, Germany had the highest incident population of NSCLC and that was 29%

 

Scope of the EGFR Market Report

• The report covers the descriptive overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.

• Comprehensive insight has been provided into the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer epidemiology and treatment in the 7MM.

• Additionally, an all-inclusive account of both the current and emerging therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.

Request for sample pages

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook

Key Findings

According to DelveInsight, Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in seven major markets was found to be USD 1,893 million in 2017 which is expected to increase during study period (2017–2030).

The United States Market Outlook

In 2017, the total market size of EGFR-NSCLC therapies was found to be USD 1,150 million in the United States which is expected to increase in the study period (2017–2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of EGFR-NSCLC therapies was found to be USD 536 million in the EU-5 countries which is expected to increase in the study period (2017–2030).

Japan Market Outlook 

 The total market size of EGFR-NSCLC therapies in Japan was found to be USD 208 million in 2017

 

Table of contents 

1. Key Insights

2. Executive Summary of EGFR-NSCLC

3. SWOT Analysis of EGFR-NSCLC

4. EGFR-NSCLC: Market Overview at a Glance

4.1. Total Market Share (%) Distribution of EGFR-NSCLC in 2017: By Country

4.2. Total Market Share (%) Distribution of EGFR-NSCLC in 2030: By Country

5. EGFR-Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview

5.1. Introduction

5.1.1. Cellular Classification of NSCLC

5.1.2. Signs and Symptoms of NSCLC

5.1.3. Risk Factors of Lung Cancer

5.1.4. Causes of NSCLC

5.1.5. Disease Biology: NSCLC

6. Diagnosis of NSCLC

6.1. Diagnostic Algorithm for NSCLC

6.2. Stages of NSCLC

6.3. Staging System

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Incident cases of NSCLC patients in the 7MM

7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM

7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM

7.4. The United States Epidemiology

7.4.1. Total Incident cases of NSCLC patients in the United States

7.4.2. Total Incident cases of NSCLC patients by Histology in the United States

7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States

7.4.4. Total EGFR NSCLC cases in the United States

7.4.5. Total EGFR NSCLC Treated patient Pool in the United States

8. EU-5 Epidemiology

8.1. Germany

8.1.1. Total Incident cases of NSCLC patients in Germany

8.1.2. Total Incident cases of NSCLC patients by Histology in Germany

8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany

8.1.4. Total EGFR NSCLC cases in Germany

8.1.5. Total EGFR NSCLC Treated patient Pool in Germany

8.2. France

8.2.1. Total Incident cases of NSCLC patients in France

8.2.2. Total Incident cases of NSCLC patients by Histology in France

8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France

8.2.4. Total EGFR NSCLC cases in France

8.2.5. Total EGFR NSCLC Treated patient Pool in France

8.3. Italy

8.3.1. Total Incident cases of NSCLC patients in Italy

8.3.2. Total Incident cases of NSCLC patients by Histology in Italy

8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy

8.3.4. Total EGFR NSCLC cases in Italy

8.3.5. Total EGFR NSCLC Treated patient Pool in Italy

8.4. Spain

8.4.1. Total Incident cases of NSCLC patients in Spain

8.4.2. Total Incident cases of NSCLC patients by Histology in Spain

8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain

8.4.4. Total EGFR NSCLC cases in Spain

8.4.5. Total EGFR NSCLC Treated patient Pool in Spain

8.5. The United Kingdom

8.5.1. Total Incident cases of NSCLC patients in the United Kingdom

8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom

8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom

8.5.4. Total EGFR NSCLC cases in the United Kingdom

8.5.5. Total EGFR NSCLC Treated patient Pool in the United Kingdom

9. Japan Epidemiology

9.1. Japan

9.1.1. Total Incident cases of NSCLC patients in Japan

9.1.2. Total Incident cases of NSCLC patients by Histology in Japan

9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan

9.1.4. Total EGFR NSCLC cases in Japan

9.1.5. Total EGFR NSCLC Treated patient Pool in Japan

10. Current Treatment Practices: NSCLC

10.1. Advanced/Metastatic NSCLC Treatment Algorithm

10.2. Chemotherapy

10.3. Targeted Therapy

10.4. Immunotherapy

10.5. Surgery

10.6. Radiation Therapy

10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC

11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020

11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018

11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of EGFR NSCLC

13. Key Endpoints in EGFR NSCLC Clinical Trials

14. Marketed Therapies

14.1. Key Cross

14.2. Tagrisso(Osimertinib): AstraZeneca

14.2.1. Product Description

14.2.2. Regulatory Milestones

14.2.3. Other Developmental Activities

14.2.4. Pivotal Clinical Trials

14.2.5. Ongoing Current Pipeline Activity

14.3. Vizimpro (Dacomitinib): Pfizer

14.3.1. Product Description

14.3.2. Regulatory Milestones

14.3.3. Other Developmental Activities

14.3.4. Pivotal Clinical Trials

14.3.5. Ongoing Current Pipeline Activity

15. Emerging Therapies

15.1. Nazartinib (EGF816): Novartis Pharmaceuticals

15.1.1. Product Description

15.1.2. Clinical Development

15.1.3. Safety and Efficacy

15.2. Capmatinib (INC280): Novartis Pharmaceuticals

15.2.1. Product Description

15.2.2. Other Development Activities

15.2.3. Clinical Development

15.2.4. Safety and Efficacy

15.3. JNJ-61186372 (JNJ-6372): Janssen Research & Development

15.3.1. Product Description

15.3.2. Other Development Activity

15.3.3. Clinical Development

15.3.4. Safety and Efficacy

15.4. Lazertinib: Yuhan Corporation/ Janssen Research & Development

15.4.1. Product Description

15.4.2. Clinical Development

15.4.3. Safety and Efficacy

15.5. TAK-788: Takeda

15.5.1. Product Description

15.5.2. Clinical Development

15.5.3. Safety and Efficacy

16. EGFR-Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis

17. EGFR Mutation—Market Size

17.1. Total Market Size of EGFR-positive NSCLC in the 7MM

17.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM

17.3. United States Market Size

17.4. EU-5 Market Size

17.4.1. Germany Market Size

17.4.2. France Market Size

17.4.3. Italy Market Size

17.4.4. Spain Market Size

17.4.5. United Kingdom Market Size

17.5. Japan Market Size

18. Market Access and Reimbursement of NSCLC Therapies

19. Market Drivers of NSCLC

20. Market Barriers of NSCLC

21. Appendix